Evidence map›Paper›PMID 40433060›Full record

ArticleSurgical case reports2025

Male Occult Primary Breast Cancer Diagnosed with Small Bowel Metastases: A Case Report.

Suguru Ogata, Uhi Toh, Kunihiro Ozaki, Yutaro Mihara, Nanae Ogata, Yuko Takao, Shuko Saku, Rie Sugihara, Fumihiko Fujita

Abstract readCase Reports
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suguru OgataDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Uhi TohDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Kunihiro OzakiDepartment of Surgery, Saiseikai Hita Hospital, Hita, Oita, Japan.
Yutaro MiharaDepartment of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Nanae OgataDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Yuko TakaoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Shuko SakuDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Rie SugiharaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Fumihiko FujitaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMale occult breast cancers are extremely rare and often difficult to diagnose. With only few cases reported, no established treatment is available. And metastatic spread to the small intestine from a tumor originating outside the peritoneal cavity is rare. However, there is a higher tendency for metastasis to the peritoneal cavity, including the small bowel, in the case of lobular carcinoma of the breast. CASE PRESENTATION: A 72-year-old man who initially presented with complaints of abdominal distention. Computed tomography revealed small bowel stenosis. Post-endoscopic stenosis dilatation, an emergency small bowel resection was performed for small bowel perforation. Postoperative histopathology revealed small bowel metastasis due to mammary gland lobular carcinoma with human epidermal growth factor receptor 2 (3+), estrogen receptor-negative, and progesterone receptor-negative status; the patient was then referred to our hospital. Imaging examinations revealed multiple lymph node metastases in the cervical region, right supraclavicular area, mediastinum, hilar region, and splenic portal. However, no obvious breast lesions or axillary lymph node metastases were identified, leading to a diagnosis of metastatic occult breast cancer. Complete response was achieved with trastuzumab plus pertuzumab plus docetaxel therapy; 30 months after chemotherapy initiation, multiple brain metastases were detected. Thus, 30 Gy whole-brain radiotherapy was performed followed by second-line treatment with trastuzumab emtansine. The patient died 4 years and 8 months after the disease onset, due to the progression of the disease with the new brain metastases.

conclusionsFor male occult breast cancer, it is important to understand the potential metastatic patterns and genetic factors, as well as to utilize comprehensive diagnostic methods for early diagnosis and disease management.

Indexed as

brain metastaseslobular carcinomamale breast canceroccult breast cancersmall bowel metastasis

Identifiers

PMID40433060
PMCPMC12105989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.